Drug Profile
SX 3507
Alternative Names: SX-3507Latest Information Update: 14 Jun 2000
Price :
$50
*
At a glance
- Originator Dainippon Pharmaceutical
- Class
- Mechanism of Action GABA A receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders
Most Recent Events
- 14 Jun 2000 Discontinued-Preclinical for Cognition disorders in Japan (Unknown route)
- 02 Nov 1998 Preclinical development for Cognition disorders in Japan (Unknown route)